JP2016530290A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016530290A5 JP2016530290A5 JP2016539635A JP2016539635A JP2016530290A5 JP 2016530290 A5 JP2016530290 A5 JP 2016530290A5 JP 2016539635 A JP2016539635 A JP 2016539635A JP 2016539635 A JP2016539635 A JP 2016539635A JP 2016530290 A5 JP2016530290 A5 JP 2016530290A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- composition
- cancer
- seq
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 100
- 239000000203 mixture Substances 0.000 claims description 55
- 150000001413 amino acids Chemical class 0.000 claims description 32
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 11
- 101001005728 Homo sapiens Melanoma-associated antigen 1 Proteins 0.000 claims description 7
- 101001005719 Homo sapiens Melanoma-associated antigen 3 Proteins 0.000 claims description 7
- 101001057131 Homo sapiens Melanoma-associated antigen D4 Proteins 0.000 claims description 7
- 102100025050 Melanoma-associated antigen 1 Human genes 0.000 claims description 7
- 102100025082 Melanoma-associated antigen 3 Human genes 0.000 claims description 7
- 101000874141 Homo sapiens Probable ATP-dependent RNA helicase DDX43 Proteins 0.000 claims description 6
- 102100035724 Probable ATP-dependent RNA helicase DDX43 Human genes 0.000 claims description 6
- -1 hTERT Proteins 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 102100039510 Cancer/testis antigen 2 Human genes 0.000 claims description 5
- 101000889345 Homo sapiens Cancer/testis antigen 2 Proteins 0.000 claims description 5
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 5
- 102100034256 Mucin-1 Human genes 0.000 claims description 5
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 4
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 4
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims description 3
- 108010002687 Survivin Proteins 0.000 claims description 3
- 102000040856 WT1 Human genes 0.000 claims description 3
- 108700020467 WT1 Proteins 0.000 claims description 3
- 101150084041 WT1 gene Proteins 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 208000030381 cutaneous melanoma Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 101150029707 ERBB2 gene Proteins 0.000 claims 2
- 230000001413 cellular effect Effects 0.000 claims 1
- 230000005867 T cell response Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical group ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1315946.2 | 2013-09-06 | ||
| GBGB1315946.2A GB201315946D0 (en) | 2013-09-06 | 2013-09-06 | Oncology vaccine |
| PCT/GB2014/052675 WO2015033140A1 (en) | 2013-09-06 | 2014-09-04 | Oncology vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016530290A JP2016530290A (ja) | 2016-09-29 |
| JP2016530290A5 true JP2016530290A5 (enExample) | 2017-10-12 |
Family
ID=49486881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016539635A Pending JP2016530290A (ja) | 2013-09-06 | 2014-09-04 | 腫瘍学ワクチン |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20160199469A1 (enExample) |
| EP (1) | EP3041493A1 (enExample) |
| JP (1) | JP2016530290A (enExample) |
| KR (1) | KR20160131998A (enExample) |
| AU (1) | AU2014316791A1 (enExample) |
| CA (1) | CA2922467A1 (enExample) |
| GB (1) | GB201315946D0 (enExample) |
| MX (1) | MX2016002937A (enExample) |
| WO (1) | WO2015033140A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3352782B1 (en) | 2015-09-25 | 2021-03-31 | ImCyse SA | Improved methods and compounds for eliminating immune responses to therapeutic agents |
| GB201520539D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520568D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd | Peptides |
| GB201520550D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| WO2017096247A1 (en) | 2015-12-04 | 2017-06-08 | Mayo Foundation For Medical Education And Research | Methods and vaccines for inducing immune responses to multiple different mhc molecules |
| PT3463436T (pt) | 2016-06-02 | 2023-12-28 | Ultimovacs As | Uma vacina em combinação com um inibidor de ponto de verificação imune para utilização no tratamento do cancro |
| AU2018212584B2 (en) * | 2017-01-27 | 2020-12-10 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| BR112019018307A2 (pt) | 2017-03-03 | 2020-03-31 | Treos Bio Zrt | Plataforma para identificação de peptídeos imunogênicos baseada em população |
| JP2020515629A (ja) | 2017-04-04 | 2020-05-28 | アヴィディア テクノロジーズ， インコーポレイテッド | 免疫応答を誘導するためのペプチドベースのワクチン、それらの製造方法および使用 |
| JP2021520414A (ja) * | 2018-04-04 | 2021-08-19 | アルティミューン インコーポレーティッド | Ｔ細胞を誘発するワクチン組成物の組合せ及びその使用 |
| ES2935702T3 (es) * | 2018-04-11 | 2023-03-09 | Enterome S A | Péptidos antigénicos para la prevención y el tratamiento del cáncer |
| US20210340201A1 (en) * | 2018-08-22 | 2021-11-04 | Fred Hutchinson Cancer Research Center | Immunotherapy targeting kras or her2 antigens |
| GB201814362D0 (en) * | 2018-09-04 | 2018-10-17 | Treos Bio Zrt | Composition and process for preparing vaccine |
| CN113329761A (zh) | 2018-09-04 | 2021-08-31 | 特雷斯生物有限公司 | 肽疫苗 |
| GB202004974D0 (en) | 2020-04-03 | 2020-05-20 | Treos Bio Ltd | Coronavirus vaccine |
| KR20230009426A (ko) * | 2020-05-12 | 2023-01-17 | 스미토모 파마 가부시키가이샤 | 암을 처치하기 위한 의약 조성물 |
| AU2023367780A1 (en) | 2022-10-25 | 2025-03-27 | Barinthus Biotherapeutics North America, Inc. | Self-assembling nanoparticles |
| WO2025227519A1 (zh) * | 2024-04-29 | 2025-11-06 | 北京臻知医学科技有限责任公司 | 一种肿瘤疫苗及其应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002511266A (ja) * | 1998-04-15 | 2002-04-16 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | 腫瘍関連核酸及びその使用 |
| US6534482B1 (en) * | 1998-05-13 | 2003-03-18 | Epimmune, Inc. | Expression vectors for stimulating an immune response and methods of using the same |
| US7030211B1 (en) * | 1998-07-08 | 2006-04-18 | Gemvax As | Antigenic peptides derived from telomerase |
| US7063854B1 (en) * | 1998-09-30 | 2006-06-20 | Corixa Corporation | Composition and methods for WTI specific immunotherapy |
| US20030224036A1 (en) * | 1999-12-13 | 2003-12-04 | Fikes John D | Hla class I a2 tumor associated antigen peptides and vaccine compositions |
| WO2001055393A2 (en) * | 2000-01-28 | 2001-08-02 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mhc class ii restricted t cell epitopes from the cancer antigen ny-eso-1 |
| AUPQ776100A0 (en) * | 2000-05-26 | 2000-06-15 | Australian National University, The | Synthetic molecules and uses therefor |
| WO2005033278A2 (en) * | 2003-09-30 | 2005-04-14 | Ludwig Institute For Cancer Research | In vivo efficacy of ny-eso-1 plus iscom |
| GB0408164D0 (en) * | 2004-04-13 | 2004-05-19 | Immune Targeting Systems Ltd | Antigen delivery vectors and constructs |
| EP1748067A1 (en) * | 2005-07-29 | 2007-01-31 | Institut Pasteur | Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes |
| GB0609121D0 (en) * | 2006-05-09 | 2006-06-21 | Univ Birmingham | Peptide Therapy |
| DK2280721T3 (da) * | 2008-04-17 | 2018-01-29 | Io Biotech Aps | Indoleamin-2, 3-dioxygenasebaseret immunterapi |
| TW201008574A (en) * | 2008-08-19 | 2010-03-01 | Oncotherapy Science Inc | INHBB epitope peptides and vaccines containing the same |
| GB201019331D0 (en) * | 2010-03-19 | 2010-12-29 | Immatics Biotechnologies Gmbh | Methods for the diagnosis and treatment of cancer based on AVL9 |
| US8987423B2 (en) * | 2010-07-22 | 2015-03-24 | Glaxosmithkline Biologicals, S.A. | MAGE antigen binding proteins |
| GB201022147D0 (en) * | 2010-12-31 | 2011-02-16 | Immune Targeting Systems Its Ltd | Formulation |
| US20120328660A1 (en) * | 2011-06-03 | 2012-12-27 | Tsuji Takemasa | Immunogenic compositions useful in provoking an integrated response to tumor antigens |
-
2013
- 2013-09-06 GB GBGB1315946.2A patent/GB201315946D0/en not_active Ceased
-
2014
- 2014-09-04 AU AU2014316791A patent/AU2014316791A1/en not_active Abandoned
- 2014-09-04 US US14/916,813 patent/US20160199469A1/en not_active Abandoned
- 2014-09-04 KR KR1020167009027A patent/KR20160131998A/ko not_active Ceased
- 2014-09-04 EP EP14762073.6A patent/EP3041493A1/en not_active Withdrawn
- 2014-09-04 JP JP2016539635A patent/JP2016530290A/ja active Pending
- 2014-09-04 CA CA2922467A patent/CA2922467A1/en not_active Abandoned
- 2014-09-04 MX MX2016002937A patent/MX2016002937A/es unknown
- 2014-09-04 WO PCT/GB2014/052675 patent/WO2015033140A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7253210B2 (ja) | Ｗｔ１抗原ペプチドおよび免疫調節剤の併用 | |
| Milani et al. | Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives | |
| Milani et al. | Recent advances in the development of breast cancer vaccines | |
| JP2018509936A5 (enExample) | ||
| RU2019106663A (ru) | Комбинированная терапия рака | |
| KR20180118702A (ko) | 방광암 및 기타 암들에 대한 면역요법에서의 사용을 위한 펩티드, 펩티드의 조합 및 세포 기반 약제들 | |
| WO2015193359A3 (en) | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll) | |
| Matijevic Glavan et al. | The exploitation of Toll-like receptor 3 signaling in cancer therapy | |
| WO2015169945A3 (en) | Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml) | |
| CN108392633A (zh) | Pcsk9抑制剂在恶性肿瘤免疫治疗中的应用 | |
| Kameshima et al. | Immunogenic enhancement and clinical effect by type‐I interferon of anti‐apoptotic protein, survivin‐derived peptide vaccine, in advanced colorectal cancer patients | |
| JP2019517544A5 (enExample) | ||
| IL240695B1 (en) | NME inhibitors and methods of using NME inhibitors | |
| CN102014937A (zh) | 基于异基因癌细胞的免疫治疗 | |
| CN109963581A (zh) | 一种il-15蛋白复合物药物组合物及其用途 | |
| JP2022512538A5 (enExample) | ||
| Nakajima et al. | Enhanced tumor immunity of WT1 peptide vaccination by interferon-β administration | |
| JP2014139185A5 (enExample) | ||
| JP2018509423A5 (enExample) | ||
| JP2018528960A5 (enExample) | ||
| Báez et al. | HER1-based vaccine: Simultaneous activation of humoral and cellular immune response | |
| JP4780540B2 (ja) | サバイビン由来癌抗原ペプチド | |
| Postow et al. | Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy | |
| CN105407916A (zh) | 二价疫苗组合物以及其用于治疗肿瘤的用途 | |
| Kim et al. | Current status and perspective of immunotherapy in gastrointestinal cancers |